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Abstract 
 
Infants and children constitute a patient group that have unique requirements in pulmonary 
drug delivery. Since their lungs develop continuously until they reach adulthood, the airways 
undergo changes in dimensions and number. Computational models have been devised on the 
growth dynamics of the airways during childhood, as well as the particle deposition 
mechanisms in these growing lungs. The models indicate that total aerosol deposition in the 
body decreases with age, while deposition in the lungs increases with age. This has been 
observed on paediatric subjects in in vivo studies. Issues unique to children in pulmonary 
drug delivery include their lower tidal volume, highly variable breathing patterns, air leaks 
from facemasks, and the off-label or unlicensed use of pharmaceutical products due to lack of 
clinical data for this age group. The aerosol devices used are essentially those developed for 
adult patients that have been adapted to paediatric use. Facemasks should be used with 
nebulisers and spacers for infants and young children. An idealised throat that mimic the 
average particle deposition in paediatric throats have been designed to obtain more clinically 
relevant aerosol dispersion data in vitro. More effort should be spent on studying particle 
deposition in the paediatric lung and developing products specific for this subpopulation to 
meet their needs. 
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Introduction 
 
‘Children are not just small adults’ is a popular cliché [1]. Indeed, much of their anatomy and 
physiology undergo development before adulthood so paediatric patients have unique 
requirements in drug delivery that differ from those of adults. For pulmonary drug delivery, 
these are mainly due to the smaller geometry of the respiratory tract and the lower inhalation 
flow rates. These fundamental characteristics consequently affect particle deposition in the 
airways and the performance of pharmaceutical inhalers. This review explores these aspects 
of paediatric inhaled drug delivery. 
 
Age classification of paediatric patients 
 
The upper age limit of paediatric patients differs depending on the regulatory authority. Since 
growth is a major trait of childhood, this patient group is heterogeneous and may be 
subdivided according to age or physiological maturity. Table 1 shows the age classifications 
from the United States of America Food and Drug Administration (FDA) [2], the European 
Agency for the Evaluation of Medicinal Products (EMEA) [3], the International Conference 
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH) [4], and the World Health Organisation (WHO) [5]. Although the naming and age 
bands of the categories between the regulatory authorities are slightly different, the broad 
divisions are similar, namely, (a) 0 ‒ 1 month, (b) 1 month ‒ 2 years, (c) 2 ‒ 12 years, and (d) 
12 ‒ 16 to 21 years. The WHO classification is more comprehensive as it distinguishes 
between the young child (2 ‒ 6 years) from the child (6 ‒ 12 years) as well as including 
categories for premature and term newborns. Since its upper age limit of 18 years old is 
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covered by the other regulatory classifications and is the most common minimum voting age 
throughout the world [6], the WHO classification will be followed in this review article. 
 
Particle deposition in the respiratory tract 
 
Theory of particle deposition in the airways 
 
The major particle deposition mechanisms in the respiratory tract are inertial impaction, 
sedimentation, and diffusion [7]. These are governed by the following relationships [8]: 
 
(Equation 1) 
 (Equation 2) 
  (Equation 3) 
 
where ρ is the particle density, d the particle diameter, D the airway diameter, L the length of 
the airway section, and Q the airflow rate. The equations above show that deposition is 
affected by dimensions of the airway, besides particle size and density. This is of particular 
significance for paediatric patients because firstly, their airways are smaller than those of 
adults. Therefore, particle deposition in the lungs in children is different to that in adults. 
Secondly, since paediatric airways undergo substantial growth before adulthood, particle 
deposition change with age during this period [8]. From the equations, airway dimensions (D 
and L) affect impaction, sedimentation, and diffusion in decreasing order of influence. This is 
because D is a cubic variable in Equation 1 so its effect is the greatest. On the other hand, the 
product DL in Equation 2 can be considered as a quadratic variable of airway dimensions and 
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L is a linear variable in Equation 3 so their power is less stepwise. It can be deduced that 
particle deposition by impaction is higher in children than in adults due to the smaller D. 
Besides having smaller airways, children also have lower respiratory flow rates [8]. The 
equations show that airflow rate (Q) has the opposite effect to airway dimensions on 
deposition. However, since Q is a linear variable, its effect is less than that of D and L in 
Equations 1 and 2. Therefore, the overall influence of the smaller airways in children 
overpowers that of the lower airflow rate [8]. This is reflected in the increase in total particle 
deposition with a decrease in age (see below). 
 
Computational deposition models 
 
Knowledge on the theoretical particle deposition in children was primarily derived from 
mathematical modelling in the 1980s and 1990s [9-13]. With the advancement of computer 
technology in later decades, computational fluid dynamics (CFD) was employed to examine 
the airflow pattern inside the airways [14-17]. However, research on deposition modelling in 
paediatric airways is less than that in adults overall. 
 
Hofmann [9] proposed a mathematical model for delineating the growth of the lung as a 
function of age. The calculation was based on the Weibel dichotomous airway model A fitted 
with morphometric data of various airway parameters at different ages. The pulmonary 
parameters included the dimensions of the trachea, main bronchi, terminal bronchioles, and 
alveoli; the number of respiratory airways and alveoli; and the total lung volume [9]. In 
accordance to morphometric observations, the lungs undergo two phases of growth in this 
model. From birth to about eight years old, new respiratory airways and the linings of these 
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with the alveoli form. Beyond eight years, the pulmonary structure is completed and further 
growth results from increases in the linear dimensions of the airways [9]. 
 
Xu and Yu [10] investigated the total and regional deposition of orally inhaled particles 
(0.01‒10 μm) in their lung model for 0 to 30-year olds with tidal breathing. Regional 
deposition was deposition in the head, tracheobronchi, and alveoli. It was found that the trend 
of total and regional deposition with respect to particle size was similar across the ages [10]. 
However, the total deposition in children was higher than that in adults for all particle sizes. 
Deposition in the head was higher in children for particles 5 μm and larger in size. On the 
other hand, deposition in the tracheobronchial and alveolar regions showed no clear 
dependency with age or particle size [10]. The head region is essentially the oropharynx, 
where large particles (> 5 μm) deposit by inertial impaction [7]. Since airway diameter is a 
cubic variable for impaction (Equation 1), deposition by this mechanism is expected to be 
significantly higher in children, whose throats are smaller [8]. This is supported by the 
finding from Xu and Yu [10]. 
 
An increase in the total deposition in children was also observed in another model [13]. This 
study utilised purely algebraic calculations rather than a branched airway model and only 
considered the inspiration phase. Total deposition was considered as filtration efficiency, η, 
which was expressed as 
 
  (Equation 4) 
 
where Y is the age in years, d the particle aerodynamic diameter, VT the tidal volume, and T 
the breathing period. The calculated total deposition (i.e. filtration efficiency) agreed well 
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with experimental data from the inhalation of monodisperse polystyrene particles by healthy 
human subjects between 5‒25 years old [13]. If d, VT, and T are kept constant in Equation 4, 
then by substituting Y with actual ages, the total deposition in a 5-year old is 2.3 times that in 
a 25-year old. Filtration efficiencies for the tracheobronchial (ηTB) and alveolar regions (ηA) 
were also derived but experimental data were not available for their verification. 
 
  when T ≤ T0   (Equation 5) 
 when T > T0   (Equation 6) 
 (Equation 7) 
 
where T0 was the standard breathing period of a given age at tidal breathing used as a point of 
reference for the actual breathing period T [13]. These equations show that while alveolar 
deposition was dependent on all the variables considered, tracheobronchial deposition was 
independent of age and tidal volume. On the contrary, Phalen et al found that 
tracheobronchial deposition decreased with age from 2‒18 years old using mathematical 
models derived from paediatric lung casts [11]. This trend was observed across various 
particle sizes (0.05‒10 μm) and breathing airflow rates at low activity and low exertion. The 
tracheobronchial dose per kilogram of body mass for 5 μm particles was six-fold lower in a 
resting adult than in a resting newborn. At high exertion, tracheobronchial deposition 
decreased with age for particles < 0.5 μm but increased with age for larger particles [11]. The 
predicted tracheobronchial deposition profiles from Phalen et al [11] under low activity 
conditions agreed well with those from Hofmann et al [12], even though the latter study used 
different equations in the calculations, considered the complete inspiratory-expiratory cycle, 
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and included both tracheobronchial and alveolar (termed ‘pulmonary’ in [12]) deposition. The 
model by Hofmann et al [12] was thus more comprehensive. It showed that under sedentary 
activity, tracheobronchial deposition decreased with age (7 months to adult) and alveolar 
deposition increased with age across all particle sizes (0.01‒10 μm). However, the total 
deposition (the sum of tracheobronchial and alveolar deposition) showed no clear 
age-dependency [12]. Total and regional deposition under maximal activity (i.e. fast 
respiratory rate) also showed complex trends [12]. It is interesting to note that the increase in 
alveolar deposition with age under sedentary activity supports the direct proportional 
relationship between ηA and Y in Equation 7. 
 
The effect of constricted airways, such as those during an asthma attack, in a paediatric CFD 
lung model on particle transport and deposition was investigated by Longest et al [16]. Upper 
and central airway models were constructed for a four-year old child, one set with normal 
airway dimensions and another with a 30% reduction in airway diameter [16]. The airflow 
rates used for the modelling were the same as those for sedentary, light activity, and heavy 
activity conditions reported in Hofmann et al [12]. It was found that airway constriction 
significantly increased the deposition of 1‒7 μm particles at airway branches and at the local 
cellular-level for all three airflow rates. This implies that drug delivery to the lungs or 
pulmonary exposure to inhaled environmental particles could be different during an asthma 
attack. 
 
In vivo deposition studies 
 
Although there are differences between the results of the deposition modelling studies 
discussed in the previous section, the general consensus is that total deposition in the 
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respiratory tract is higher in younger children. However, deposition in the deeper airways 
would be lower in paediatric subjects because oropharyngeal deposition is more significant. 
This consequently reduces the amount of particles that travel further downstream [8]. The 
higher total and oropharyngeal deposition [18-20], as well as lower lung deposition [19-24], 
in younger children have been observed in in vivo studies. The higher total and oropharyngeal 
deposition for particles ≥ 5 μm was predicted by the paediatric model by Xu and Yu discussed 
above [10], whereas the lower lung deposition with age is in line with the model by Phalen et 
al [11]. However, no single paediatric model so far can accurately predict the total and 
regional depositions. The findings derived from some models do not even agree with each 
other. This is because there is limited anatomical and physiological data of the young airways. 
In addition, in vivo deposition data on paediatric subjects are limited for verifying the models. 
 
A number of in vivo deposition measurements conducted on children included direct 
scintigraphic imaging studies using radiolabelled aerosols [19-22, 25-30] and indirect studies 
using calculated deposition [18, 31] or pharmacokinetic/pharmacodynamic assessments 
[31-33]. It is clear from these studies that nebulised droplets and particles produced from 
metered dose inhalers (MDIs) can deposit in the paediatric airways in vivo. However, the 
proportion of drug that reaches the lungs is generally low. The mean lung dose of 
technetium-99m-labelled radiolabelled aerosols given by jet nebulisers and suspension MDIs 
with spacers was typically 5% of the administered dose or lower [21, 22, 25, 26, 28, 33, 34]. 
The mode of breathing was tidal through facemasks in these studies. Filtration of particles by 
the nasal cavity has been suggested as a major cause of the low deposition in the lungs [33]. 
The low tidal volume in children may have also decreased the aerosol inhaled (see next 
section). 
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Another factor for the low lung doses in the studies mentioned above was the large droplet or 
particle sizes employed, which were > 3 μm. Higher lung deposition could be achieved when 
the particle size was reduced. This was seen in children who used the hydrofluoroalkane 
(HFA) MDI solution formulation of beclomethasone dipropionate (QVAR™). This product 
produces droplets with a mass median aerodynamic diameter (MMAD) of 1.1 μm so 
deposition in the peripheral airways should be high [19]. Indeed, the mean lung dose of the 
QVAR™ Autohaler, a breath-actuated MDI used without a spacer, ranged from 36.9‒54.1% 
of the ex-actuator dose in children aged 5‒14 years. Even higher lung doses could be 
achieved when a conventional QVAR™ MDI coupled to an Aerochamber Plus™ spacer was 
used with a slow maximal inhalation followed by a 5‒10 s breath-hold [20]. The mean lung 
dose ranged from 56.6‒58.4% of the ex-actuator dose in children aged 5‒17 years [20]. In 
contrast, the same device configuration used with tidal breathing yielded mean lung doses of 
35.4, 47.5, and 54.9% for subjects aged 5‒7, 8‒10, and 11‒17 years, respectively [20]. The 
breath-holding manoeuver thus eliminated the age-dependency of the lung dose. It also 
reduced oropharyngeal and gastrointesintal drug deposition [20]. 
 
Special requirements in paediatric respiratory drug delivery 
 
There are generic requirements for delivering pharmaceutical aerosols to both children and 
adults, namely, optimal particle size range (1‒5 μm aerodynamic diameter), minimal 
oropharyngeal deposition, and simple, affordable, and reliable aerosol devices [24]. However, 
paediatric patients also have special needs that are absent, or are not as significant, in adults. 
The lower tidal volume of children obviously reduces dose delivery [24]. Infants and children 
also have highly variable breathing patterns. Their inspiratory flow rates range from nearly 0 
to about 40 L/min [24]. Moreover, infants cannot adopt any stipulated breathing patterns so 
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they can only breathe tidally through the nose [35]. Thus they must need facemasks for 
aerosol administration. Children of two and a half to three years old would have sufficient 
ability to use a mouthpiece [35]. However, if the infant or child is emotionally upset and cries, 
then drug delivery will be adversely affected. The breathing pattern will change and the 
inspiratory flow rate will increase, which leads to higher deposition in the proximal airways 
[24, 35]. The facemask seal will also loosen when child is upset and cause aerosol leakage 
[35]. The problems discussed above need to be considered when designing, testing, and using 
pharmaceutical aerosol products to optimise delivery in children. 
 
Another issue with paediatric drug delivery, not unique to the inhalation route, is the 
unlicensed or off-label use of marketed products in infants and young children [36, 37]. 
Unlicensed use is the use of a product that is not approved in a particular age group (or in 
humans) [37]. Off-label use is the use of a product approved for the given age group but it is 
used in an unapproved manner or dosage regimen [37]. Most pharmaceutical products were 
approved from clinical studies in adults or older children (≥ 6 years old) [36]. Pharmaceutical 
companies have little incentives to conduct trials on younger subjects due to the complexity 
and high cost. Therefore, paediatricians are faced with the difficulty of choosing the 
appropriate drug, dosage, and device because there is a lack of clinical data that can serve as 
a guide [36]. Nevertheless, unlicensed and off-label uses of inhalation products are very 
common [37], especially in infants and children < 6 years old [36]. The gap in drug use 
knowledge in this age group is an unmet need that needs to be addressed. Collaborative 
research and sharing of data between academic and industrial researchers may assist 
regulators and prescribers in improving and standardising drug use in young paediatric 
patients [36]. 
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Pharmaceutical aerosol devices 
 
Nebulisers 
 
Nebulisers had been the most commonly used aerosol device in children because the patient 
can inhale the droplets at a natural pace, without the need for coordination. The jet nebuliser 
is the oldest type that uses a compressed gas to atomise the liquid. The gas is usually air that 
is pumped by an electrical air compressor. Treatment times are long, ranging from 5‒15 
minutes. It is also bulky so it is usually used at home or in the hospital. Their droplet size and 
drug output are dependent on the model of the nebuliser and the breathing pattern [38-40]. 
Ultrasonic nebulisers are smaller than jet nebulisers and produce droplets by the application 
of ultrasonic waves through the liquid from a piezoelectric element at the bottom of the 
reservoir. However, the energy input heats up the liquid so they are not suitable for protein 
drugs. The newest type of nebuliser is the vibrating mesh nebuliser. When in operation, a 
mesh with small laser-drilled holes rapidly vibrates against the surface of the liquid and eject 
out the droplets. The vibrating mesh nebuliser has shorter treatment times and lower residual 
volumes (i.e. less liquid wastage) than jet and ultrasonic nebulisers. 
 
It has long been demonstrated that delivering drugs using a MDI with a spacer can achieve 
the same therapeutic outcomes as that using a nebuliser [24]. This changeover is practical as 
long as the drug of interest is available in both MDI and nebule forms. Comparisons between 
MDIs and nebulisers are discussed in the next section. 
 
Metered dose inhalers and spacers 
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To use MDIs properly, the patient needs to coordinate actuation and inhalation. This is 
difficult for children thus spacers are used as an accessory to hold the aerosol while the child 
breathes tidally. The one-way inhalation valve inside the spacer must have low resistance so 
that it opens readily at low airflow rates. Besides eliminating the need for coordination, it 
provides space and time for the propellant droplets to evaporate and decelerate, reducing the 
particle size. This in turn decreases oropharyngeal deposition and potential systemic 
absorption through the gastrointestinal tract. Discomfort from the ‘cold Freon’ effect, which 
is due to the flash evaporation of the propellant, is also avoided. The volume of the spacer is 
important because if it is much larger than the tidal volume then the dose will not be 
sufficiently inhaled by the patient. Tidal volumes range from 75 mL for a 6-month old child, 
to 325 mL for an 8-year old, and to 750 for an adult male [8]. Typical spacer volumes range 
from 200‒500 mL. The large spacers should not be used on infants or children with small 
tidal volumes. 
 
There are various commercially available spacers with different dimensions, geometries, 
volumes, and designs. These differences, together with the MDI formulation and tidal 
breathing pattern, can affect the fine particle dose delivered [41]. Using replicas of infant (7 
month old) and child (4 years old) faces, particles produced from Ventolin
®
 and Beclovent
®
 
MDIs through a Space-Chamber
®
 spacer were collected through the simulated nostrils and 
into an Andersen Mark II cascade impactor while tidal breathing occurred through the spacer 
[42]. It was found that less drug was collected with the infant face replica than the child 
replica. This is analogous to the lower total deposition in younger subjects discussed above. 
The difference was due to more large particles being collected with the child replica. The 
amount of fine particles < 2.1 μm for Ventolin® and < 3.3 μm for Beclovent® was not affected 
by the face replicas [42]. 
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The usefulness of spacers has been demonstrated in many studies. Asthmatic children (mean 
age = 6 years) who used MDIs with spacer showed earlier resolution of wheezing, fewer days 
of cough after an asthma attack, and shorter absence from school after an asthma attack 
compared to those who used MDIs alone [43]. In studies that compared the MDIs plus spacer 
to nebulised therapy, the former treatment was always demonstrated to be as effective as, or 
better than, the latter [22, 32, 44, 45]. Supported by these findings, patients are encouraged to 
use MDIs and spacers instead of nebulisers, especially because the former are more portable 
and easier to use. 
 
Facemasks 
 
Facemasks are interface accessories commonly used with nebulisers and spacers for infants 
and young children. It is important that the facemask establishes a tight seal on the child’s 
face because even a small leak can significantly decrease aerosol delivery efficiency. This 
effect has been shown in an in vivo study on wheezy children (18‒36 months old) [46]. When 
they inhaled radiolabelled salbutamol from a MDI plus a spacer, the lung deposition with 
respect to the metered dose was 0.2% in children who inhaled from a loosely fitted facemask, 
0.6% in screaming children with a tightly fitted facemask, and 4.8% in those who breathed 
normally [46]. The corresponding figures for nebulised radiolabelled salbutamol in those 
children were slightly higher but the trend was similar. These data indicate that not only the 
tightness of the facemask is crucial; the mode of breathing also greatly affects drug delivery. 
Indeed, an in vitro study using a breathing simulator and a paediatric face model with an 
inhaled mass filter connected to the simulated mouth, a crying breathing pattern reduced the 
inhaled drug mass to < 1% of the labelled dose for both nebulisers and MDI plus spacers [47]. 
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Crying and screaming are real problems in uncooperative or upset children so approaches that 
minimise the distress must be developed to encourage tidal breathing [35]. 
 
Besides ensuring good aerosol delivery, the seal and shape of the facemask also affects facial 
and ocular deposition of the drug, which should be minimised [48, 49]. The design of the 
facemask such as minimal dead space, shape that fits snuggly to the contours of the face, and 
flexible construction material should be considered during product development. Two 
excellent and comprehensive reviews have been published on these aspects [50, 51]. 
However, even a facemask with the best design will fail if a child is uncooperative. The carer 
may keep the child calm with some games or distractions during aerosol administration [35]. 
 
Dry powder inhalers 
 
Dry powder inhalers (DPIs) are passive devices that require the user’s inspiratory effort to 
disperse the powder for inhalation. They are not recommended for children < 4 years old 
because younger ones cannot generate sufficiently high airflow through the devices [24, 36]. 
In vivo deposition of radiolabelled budesonide particles from a Turbuhaler
®
 was tested on 3 
to 16-year old cystic fibrosis subjects with normal lung function [30]. The lung dose was 
positively correlated with age and peak inspiratory flow. This is understandable because 
Turbuhaler
®
 has relatively high airflow resistance so its performance is flow-dependent. 
Interestingly, after the lung dose was normalised against body weight for subjects > 6 years 
old there was no correlation with age [30]. This implies that although younger children 
inhaled lower lung doses due to the lower peak flows, the situation was counter-balanced by 
their lower body weights. Budesonide delivered from the Turbuhaler
®
 has been shown to be 
more effective in 5 to 15-year old asthmatic patients than the same drug administered from a 
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MDI with a Nebuhaler spacer [52]. This was reflected in the lower usage of a bronchodilator 
(i.e. lower asthma attack incidence) in patients who used the Turbuhaler
®
, as well as no 
deterioration in asthma control when the Turbuhaler
®
 budesonide dose was halved [52]. 
 
Unlike the Turbuhaler
®
, the aerosol performance of the Diskus™ inhaler is independent of 
airflow rate in vitro and in vivo [53]. Ninety-nine per cent of children from 3‒10 years old 
could generate a flow rate of 30 L/min through the inhaler. On the other hand, 26% could 
achieve 90 L/min [53]. Fifty micrograms of salmeterol was inhaled by children aged 8‒15 
years at 30 or 90 L/min. The protective effect of the drug against bronchoconstrict ion was not 
significantly different between the two flow rates [53]. 
 
Soft Mist™ inhaler 
 
The Respimat
®
 Soft Mist™ inhaler (SMI) is a multidose inhaler that produces a fine mist 
from forcing a metered volume of aqueous drug solution through a set of fine channels in the 
nozzle [54]. It does not contain propellants. Rather, the atomisation energy comes from a 
tensioned spring inside the inhaler. The relatively long atomisation time (about 1.2 s) renders 
the mist slow-moving, hence reduces oropharyngeal deposition compared to MDIs [54]. A 
clinical study had been conducted on asthmatic patients aged 6‒15 years to compare the 
efficacy of the combination treatment with ipratropium bromide and fenoterol hydrobromide 
delivered from the SMI and that from a MDI with spacer [54]. It was found that the drugs 
administered using the SMI was at least as effective, and was a safe as, that with the MDI and 
spacer [54]. 
 
Paediatric idealised throat 
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Aerosol performance is usually assessed in vitro by sampling the particles using a cascade 
impactor. From the amount of drug deposited on the impactor stages, the fine particle dose < 
5 μm can be obtained as an indicator of the potentially inhalable dose. As mentioned above, 
the lung dose is greatly affected by deposition in the nasal and oropharyngeal region. The 
conventional United States Pharmacopeia induction port for in vitro impaction experiments 
constitutes a 90° bend. This design is too simple to faithfully simulate particle deposition in a 
human throat, whether for adults or children. Thus it is important to use an aerosol induction 
port that yields clinically relevant particle deposition. Anatomical replicas of the paediatric 
nasal cavity and upper airways have been constructed from three-dimensional computed 
tomography (CT) or magnetic resonance imaging (MRI) scans of infants and children [55-61]. 
Their usefulness in replicating paediatric throat deposition has been demonstrated in vitro. 
However, each anatomical replica is different so there is a need to design a simplified throat 
model that can provide representative deposition data to standardise usage with impactors. 
The commercially available Alberta Idealised Throat is such a model developed from CT 
scans of adult throats and subsequent simplification [62]. A downscaled version of this throat 
successfully replicated the average paediatric oropharyngeal deposition in throat replicas of 6 
to 14-year olds [63]. A similar paediatric idealised throat representing the upper airway of a 4 
to 5‒year old has recently been used to assess the performance of two dry powder inhalers on 
a Next Generation Impactor (NGI) [64]. 
 
Conclusion 
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Paediatric patients constitute a subpopulation with special needs for pulmonary drug delivery. 
More knowledge is needed on the anatomical and physiological changes in their lungs during 
growth. Academic and industrial researchers should devote more efforts in paediatric drug 
delivery. This will facilitate the design and use of pharmaceutical aerosol products to suit this 
special patient group. 
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Table 1. Age classifications of paediatric patients from the FDA [2], EMA [3], ICH [4], and WHO [5]. 
FDA  
Neonates 0 ‒ 28 days 
Infants 29 days ‒ Less than 2 years 
Children 2 years ‒ Less than 12 years 
Adolescents 12 years ‒ 21 years (up to, but not including the 22nd 
birthday) 
EMA and ICH  
Preterm newborn infants  
Term newborn infants 0 ‒ 27 days 
Infants and toddlers 28 days ‒ 23 months 
Children 2 ‒ 11 years 
Adolescents 12 ‒ 16 to 18 years depending on the region 
WHO  
Premature newborns < 38 weeks gestational age 
Term newborns > 38 weeks gestational age 
Neonate 0 ‒ 30 days 
Infant 1 month ‒ 2 years 
Young child 2 ‒ 6 years 
Child 6 ‒ 12 years 
Adolescent 12 ‒ 18 years 
 
 
